Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Recentin

 
National Institutes of Health

Related topics

Related topics

1 relation
AZD2171

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
PURPOSE Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signaling with activity against all… Expand
2010
2010
An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients… Expand
2009
2009
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
PurposeTo evaluate safety and tolerability of cediranib, a highly potent and selective vascular endothelial growth factor… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2009
Highly Cited
2009
Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function
PurposeCediranib (recentin, AZD2171) is an oral small-molecule multiple receptor tyrosine kinases inhibitor. Here we investigate… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2009
2009
Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
Cediranib (RECENTIN, AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular… Expand
Review
2009
Review
2009
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
Angiogenesis, the process whereby tumors develop new blood vessels to facilitate growth and metastasis, is a pivotal event in… Expand
  • table 1
Highly Cited
2008
Highly Cited
2008
Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant…
Purpose: Inhibition of vascular endothelial growth factor-A (VEGF) signaling is a key therapeutic approach in oncology given the… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2008
2008
Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant…
PURPOSE Inhibition of vascular endothelial growth factor-A (VEGF) signaling is a key therapeutic approach in oncology given the… Expand
Highly Cited
2008
Highly Cited
2008
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Solid tumors express a range of factors required to sustain their growth and promote their dissemination. Among these are… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
2008
2008
Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.
A number of pre-clinical studies have suggested that blocking vascular endothelial growth factor (VEGF) signalling can be… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE